Hellerup, Denmark

Rasmus Ohlenschlager

This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: Amgen Inc.. Active years: 2024-2025.

USPTO Granted Patents = 4 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 38(Granted Patents)


Company Filing History:


Years Active: 2024-2025

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Rasmus Ohlenschlager: Innovator in Drug Delivery Technology

Introduction

Rasmus Ohlenschlager is a notable inventor based in Hellerup, Denmark. He has made significant contributions to the field of drug delivery technology, holding a total of 4 patents. His work focuses on developing innovative solutions that enhance the efficiency and effectiveness of drug administration.

Latest Patents

Among his latest inventions is a handheld drug delivery device, which aims to improve the convenience and precision of medication delivery. This device represents a significant advancement in the healthcare sector, providing patients with a user-friendly option for administering their treatments.

Career Highlights

Rasmus Ohlenschlager is currently employed at Amgen Inc., a leading biotechnology company known for its commitment to innovative therapies. His role at Amgen allows him to collaborate with other experts in the field and contribute to groundbreaking research and development.

Collaborations

Throughout his career, Rasmus has worked alongside talented colleagues, including Peter Dan Kaare Soelberg and Kasper Poder. These collaborations have fostered a creative environment that encourages the exchange of ideas and the development of new technologies.

Conclusion

Rasmus Ohlenschlager's contributions to drug delivery technology exemplify the impact of innovation in healthcare. His patents and collaborative efforts continue to shape the future of medical treatments, making a difference in the lives of patients worldwide.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…